Korro Bio (KRRO) Shares Outstanding (2018 - 2026)
Korro Bio's (KRRO) quarterly Shares Outstanding (Entity) came in at $11.6 million in Q1 2026, up 23.54% YoY from $9.4 million in Q1 2025, and up 23.16% on a QoQ basis from $9.4 million in Q4 2025.
Korro Bio (KRRO) Shares Outstanding (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Shares Outstanding (Entity) data on file, last reported at $11.6 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 23.54% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (up 23.54% YoY) and the FY2025 annual result came in at $9.4 million, changed 0.43% from the prior year.
- Shares Outstanding (Entity) grew to $11.6 million in Q1 2026, from $9.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $11.6 million in Q1 2026 to a low of $255175.0 in Q4 2022.
- A 5-year average of $5.3 million and a median of $8.0 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) tumbled 63.14% — and 2024, when it surged 3256.43%.
- Tracing KRRO's Shares Outstanding (Entity) over 5 years: stood at $255175.0 in 2022, then surged by 499.32% to $1.5 million in 2023, then surged by 513.16% to $9.4 million in 2024, then gained by 0.43% to $9.4 million in 2025, then increased by 23.16% to $11.6 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $11.6 million (Q1 2026), $9.4 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Korro Bio | 231.77 Mn | 116.73 Mn | - | 17.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.62 Mn |
| Mar 31, 2026 | 11.60 Mn |
| Dec 31, 2025 | 9.40 Mn |
| Sep 30, 2025 | 9.39 Mn |
| Jun 30, 2025 | 9.39 Mn |
| Mar 31, 2025 | 9.38 Mn |
| Dec 31, 2024 | 8.92 Mn |
| Sep 30, 2024 | 9.30 Mn |
| Jun 30, 2024 | 8.99 Mn |
| Mar 31, 2024 | 8.02 Mn |
| Dec 31, 2023 | 1.53 Mn |
| Sep 30, 2023 | 738,445.00 |
| Jun 30, 2023 | 276,482.00 |
| Mar 31, 2023 | 271,522.00 |
| Dec 31, 2022 | 255,175.00 |
| Sep 30, 2022 | 704,954.00 |
| Jun 30, 2022 | 699,528.00 |
| Mar 31, 2022 | 696,214.00 |
| Dec 31, 2021 | 687,025.00 |
| Sep 30, 2021 | 688,975.00 |